The impact of chronic kidney disease on medication choice and pharmacologic management in patients with heart failure

References

• Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics–2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007;115:e69–171.
   PubMed Web of Science ®Google Scholar
• National Heart L, and Blood Institute. National Institutes of Health. Congestive heart failure in the United States: a new epidemic. 1996.
   Google Scholar
• Duni A, Liakopoulos V, Rapsomanikis KP, et al. Chronic kidney disease and disproportionally increased cardiovascular damage: does oxidative stress explain the burden? Oxid Med Cell Longev. 2017. 2017:9036450. Epub 2017 Nov 23. Review.DOI:10.1155/2017/9036450
   Google Scholar
• Bagshaw SM, Cruz DN, Aspromonte N, et al. Epidemiology of cardio-renal syndromes: workgroup statements from the 7th ADQI consensus conference. Nephrol Dial Transplant. 2010;25(5):1406–1416.
   PubMed Web of Science ®Google Scholar
• Ishigami J, Grams ME, Naik RP, et al. Hemoglobin, albuminuria, and kidney function in cardiovascular risk: the ARIC (Atherosclerosis Risk in Communities) Study. J Am Heart Assoc. 2018 Jan 12;7(2):pii: e007209.
   PubMed Web of Science ®Google Scholar
• Ramphul R, Fernandez M, Firoozi S, et al. Assessing cardiovascular risk in chronic kidney disease patients prior to kidney transplantation: clinical usefulness of a standardised cardiovascular assessment protocol. BMC Nephrol. 2018 Jan 8;19(1):2.
   PubMedGoogle Scholar
• Wang AY, Wang M, Lam CW, et al. Heart failure in long-term peritoneal dialysis patients: a 4-year prospective analysis. Clin J Am Soc Nephrol. 2011;6(4):805–812.
   PubMed Web of Science ®Google Scholar
• Carubelli V, Metra M, Lund LH. Negotiating renal dysfunction when treating patients with heart failure. Expert Rev Cardiovasc Ther. 2018 Jan; 2:1–10.
   Google Scholar
• Özkahya M, Ok E, Cirit M, et al. Regression of left ventricular hypertrophy in haemodialysis patient by ultrafiltration and reduced salt intake without antihypertensive drugs. Nephrol Dial Transplant. 1998;13(6):1489–1493.
   PubMed Web of Science ®Google Scholar
• Gunal AI, Karaca I, Aygen B, et al. Strict fluid volume control and left ventricular hypertrophy in hypertensive patients on chronic haemodialysis: a cross-sectional study. J Int Med Res. 2004;32(1):70–77.
   PubMed Web of Science ®Google Scholar
• Herzog CA, Asinger RW, Berger AK, et al. Cardiovascular disease in chronic kidney disease. A clinical update from kidney disease: improving global outcomes (KDIGO). Kidney Int. 2011;80(6):572–586.
   PubMed Web of Science ®Google Scholar
• Pitt B, Rossignol P. Mineralocorticoid receptor antagonists in high-risk heart failure patients with diabetes mellitus and/or chronic kidney disease. J Am Heart Assoc. 2017 Dec 23;6(12):pii: e008054.
   Web of Science ®Google Scholar
• Abdo AS, Basu A, Geraci SA. Managing chronic heart failure patient in chronic kidney disease. Am J Med. 2011;124(1):26–28.
   PubMed Web of Science ®Google Scholar
• Hasselblad V, Gattis Stough W, Shah MR, et al. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail. 2007;9:1064–1069.
   PubMed Web of Science ®Google Scholar
• Felker GM, O’Connor CM, Braunwald E. Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil? Circ Heart Fail. 2009;2:56–62.
   PubMed Web of Science ®Google Scholar
• Eshaghian S, Horwich TB, Fonarow GC. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol. 2006;97:1759–1764.
   PubMed Web of Science ®Google Scholar
• Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364:797–805.
   PubMed Web of Science ®Google Scholar
• Mancini DM, Katz SD, Lang CC, et al. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation. 2003;107(2):294–299.
   PubMed Web of Science ®Google Scholar
• Shah SR, Alweis R. Acute coronary artery dissection: a review of the literature and current evidence. Cardiol Rev. 2017 Dec 12. DOI:10.1097/CRD.0000000000000186
   Web of Science ®Google Scholar
• Silverberg DS, Wexler D, Blum M, et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol. 2000;35(7):1737–1744.
   PubMed Web of Science ®Google Scholar
• van der Meer P, Groenveld HF, Januzzi JL Jr., et al. Erythropoietin treatment in patients with chronic heart failure: a meta-analysis. Heart. 2009;95(16):1309–1314.
   PubMed Web of Science ®Google Scholar
• Levin A, Thompson CR, Ethier J, et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis. 1999;34(1):125–134.
   PubMed Web of Science ®Google Scholar
• Martinez-Vea A, Marcas L, Bardají A, et al. Role of oxidative stress in cardiovascular effects of anemia treatment with erythropoietin in predialysis patients with chronic kidney disease. Clin Nephrol. 2012;77(3):171–181.
   PubMed Web of Science ®Google Scholar
• Shah SR, Uddin MF, Lateef N, et al. Evolocumab to reduce cardiovascular events: results of the (FOURIER) multinational trial. J Community Hosp Intern Med Perspect. 2017 Jul 13;7(3):199–200.
   PubMed Web of Science ®Google Scholar
• Foley RN, Parfrey PS, Morgan J, et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int. 2000;58(3):1325–1335.
   PubMed Web of Science ®Google Scholar
• Malyszko J, Anker SD. Iron therapy in heart failure patients without anaemia: possible implications for chronic kidney disease patients. Clin Kidney J. 2017 Dec;10(Suppl 1):i25–i31.
   PubMedGoogle Scholar
• Drüeke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355(20):2071–2084.
   PubMed Web of Science ®Google Scholar
• Verjans R, Peters T, Beaumont FJ, et al. MicroRNA-221/222 family counteracts myocardial fibrosis in pressure overload-induced heart failure. Hypertension. 2018 Feb;71(2):280–288.
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Burdmann EA, Chen C, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361(21):2019–2032.
   PubMed Web of Science ®Google Scholar
• Gaggin HK, Dec GW. the role of treatment for anemia as a therapeutic target in the management of chronic heart failure: insights after RED-HF. Curr Treat Options Cardiovasc Med. 2014 Jan;16(1):279.
   PubMedGoogle Scholar
• Locatelli F, Aljama P, Canaud B, et al. Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the trial to reduce cardiovascular events with Aranesp therapy (TREAT) study. Nephrol Dial Transplant. 2010;25(9):2846–2850.
   PubMed Web of Science ®Google Scholar
• Richette P, Latourte A, Bardin T. Cardiac and renal protective effects of urate-lowering therapy. Rheumatology (Oxford). 2018 Jan 1;57(suppl_1):i47–i50.
   PubMedGoogle Scholar
• Bernardi D, Bernini L, Cini G, et al. Asymmetric septal hypertrophy and sympathetic overactivity in normotensive hemodialyzed patients. Am Heart J. 1985;109(3, part 1):539–545.
   PubMed Web of Science ®Google Scholar
• Badve SV, Roberts MA, Hawley CM, et al. Effects of beta-adrenergic antagonists in patients with chronic kidney disease: a systematic review and meta-analysis. J Am Coll Cardiol. 2011;58(11):1152–1161.
   PubMed Web of Science ®Google Scholar
• Ezekowitz J, McAlister FA, Humphries KH, et al. The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. J Am Coll Cardiol. 2004;44(8):1587–1592.
   PubMed Web of Science ®Google Scholar
• Shlipak MG, Browner WS, Noguchi H, et al. Comparison of the effects of angiotensin converting-enzyme inhibitors and beta blockers on survival in elderly patients with reduced left ventricular function after myocardial infarction. Am J Med. 2001;110(6):425–433.
   PubMed Web of Science ®Google Scholar
• Abbott KC, Trespalacios FC, Agodoa LY, et al. β-blocker use in long-term dialysis patients: association with hospitalized heart failure and mortality. Arch Intern Med. 2004;164(22):2465–2471.
   PubMedGoogle Scholar
• Ghali JK, Wikstrand J, van Veldhuisen DJ, et al. The influence of renal function on clinical outcome and response to β-blockade in systolic heart failure: insights from metoprolol CR/XL randomized intervention trial in chronic HF (MERIT-HF). J Card Fail. 2009;15(4):310–318.
   PubMed Web of Science ®Google Scholar
• Castagno D, Jhund PS, McMurray JJV, et al. Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trial. Eur J Heart Fail. 2010;12(6):607–616.
   PubMed Web of Science ®Google Scholar
• Shah SR, Fatima M, Dharani AM, et al. Bioresorbable vascular scaffold versus metallic stent in percutaneous coronary intervention: results of the AIDA trial. J Community Hosp Intern Med Perspect. 2017 Oct 18;7(5):307–308.
   PubMed Web of Science ®Google Scholar
• Cice G, Ferrara L, Di Benedetto A, et al. Dilated cardiomyopathy in dialysis patients—beneficial effects of carvedilol: a double-blind, placebo-controlled trial. J Am Coll Cardiol. 2001;37(2):407–411.
   PubMed Web of Science ®Google Scholar
• Cice G, Ferrara L, D’Andrea A, et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol. 2003;41(9):1438–1444.
   PubMed Web of Science ®Google Scholar
• Wang N, Gallagher R, Sze D, et al. Predictors of frequent readmissions in patients with heart failure. Heart Lung Circ. 2017 Nov 14; pii: S1443–9506(17)31489–0. DOI:10.1016/j.hlc.2017.10.024
   Google Scholar
• Acquarone N, Castello C, Antonucci G, et al. Pharmacologic therapy in patients with chronic heart failure and chronic kidney disease: a complex issue. J Cardiovasc Med. 2009;10(1):13–21.
   Google Scholar
• Shah SR, Fatima K, Ansari M. Recovery of myofilament function through reactivation of glycogen synthase kinase 3β (GSK-3β): mechanism for cardiac resynchronization therapy. J Interv Card Electrophysiol. 2014 Dec;41(3):193–194.
   PubMed Web of Science ®Google Scholar
• McAlister FA, Ezekowitz J, Tonelli M, et al. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation. 2004;109(8):1004–1009.
   PubMed Web of Science ®Google Scholar
• McCullough PA, Sandberg KR, Yee J, et al. Mortality benefit of angiotensin-converting enzyme inhibitors after cardiac events in patients with end-stage renal disease. J Renin Angiotensin Aldosterone Syst. 2002 Sep;3(3):188–191.
   PubMed Web of Science ®Google Scholar
• Frances CD, Noguchi H, Massie BM, et al. Are we inhibited? Renal insufficiency should not preclude the use of ACE inhibitors for patients with myocardial infarction and depressed left ventricular function. Arch Intern Med. 2000;160(17):2645–2650.
   PubMedGoogle Scholar
• Ahmed A, Love TE, Sui X, et al. Effects of angiotensin-converting enzyme inhibitors in systolic heart failure patients with chronic kidney disease: a propensity score analysis. J Card Fail. 2006;12(7):499–506.
   PubMed Web of Science ®Google Scholar
• Tokmakova MP, Skali H, Kenchaiah S, et al. Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the survival and ventricular enlargement (SAVE) study. Circulation. 2004;110(24):3667–3673.
   PubMed Web of Science ®Google Scholar
• Bowling CB, Sanders PW, Allman RM, et al. Effects of enalapril in systolic heart failure patients with and without chronic kidney disease: insights from the SOLVD treatment trial. Int J Cardiol. 2013;167(1):151–156.
   PubMed Web of Science ®Google Scholar
• London GM, Pannier B, Guerin AP, et al. Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease: comparative effects of ACE inhibition and calcium channel blockade. Circulation. 1994;90(6):2786–2796.
   PubMed Web of Science ®Google Scholar
• Shah SR, Alweis R, Shah SA, et al. Effects of colchicine on pericardial diseases: a review of the literature and current evidence. J Community Hosp Intern Med Perspect. 2016 Jul 6;6(3):31957. eCollection 2016.
   PubMed Web of Science ®Google Scholar
• Guerin AP, Blacher J, Pannier B, et al. Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation. 2001;103(7):987–992.
   PubMed Web of Science ®Google Scholar
• Zannad F, Kessler M, Lehert P, et al. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int. 2006;70(7):1318–1324.
   PubMed Web of Science ®Google Scholar
• Chang TI, Shilane D, Brunelli SM, et al. Angiotensin-converting enzyme inhibitors and cardiovascular outcomes in patients on maintenance hemodialysis. Am Heart J. 2011;162(2):324–330.
   PubMed Web of Science ®Google Scholar
• Berger AK, Duval S, Manske C, et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease. Am Heart J. 2007;153(6):1064–1073.
   PubMed Web of Science ®Google Scholar
• Shireman TI, Mahnken JD, Phadnis MA, et al. Comparative effectiveness of renin-angiotensin system antagonists in maintenance dialysis patients. Kidney & Blood Pressure Research. 2016;41(6):873–885.
   PubMed Web of Science ®Google Scholar
• Flather MD, Yusuf S, Køber L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. The Lancet. 2000;355(9215):1575–1581.
   PubMed Web of Science ®Google Scholar
• Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med. 2000;160(5):685–693.
   PubMed Web of Science ®Google Scholar
• Gradman AH, Papademetriou V. Combined renin-angiotensin-aldosterone system inhibition in patients with chronic heart failure secondary to left ventricular systolic dysfunction. Am Heart J. 2009;157(6, supplement):S17–S23.
   PubMed Web of Science ®Google Scholar
• Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med. 2004;351(6):585–622.
   PubMed Web of Science ®Google Scholar
• Granger CB, McMurray JJV, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trial. The Lancet. 2003;362(9386):772–776.
   PubMed Web of Science ®Google Scholar
• Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345(23):1667–1675.
   PubMed Web of Science ®Google Scholar
• Wong M, Staszewsky L, Latini R, et al. Valsartan benefits left ventricular structure and function in heart failure: val-HeFT echocardiographic study. J Am Coll Cardiol. 2002;40(5):970–975.
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349(20):1893–1906.
   PubMed Web of Science ®Google Scholar
• Shah SR, Alweis R, Najim NI, et al. Use of dark chocolate for diabetic patients: a review of the literature and current evidence. J Community Hosp Intern Med Perspect. 2017 Sep 19;7(4):218–221.
   PubMed Web of Science ®Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861–869.
   PubMed Web of Science ®Google Scholar
• Tobe SW, Clase CM, Gao P, et al. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies. Circulation. 2011;123(10):1098–1107.
   PubMed Web of Science ®Google Scholar
• Ahmed A, Fonarow GC, Zhang Y, et al. Renin-angiotensin inhibition in systolic heart failure and chronic kidney disease. Am J Med. 2012;125(4):399–410.
   PubMed Web of Science ®Google Scholar
• Cice G, Di Benedetto A, D’Isa S, et al. Effects of telmisartan added to angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure: a double-blind, placebo-controlled trial. J Am Coll Cardiol. 2010;56(21):1701–1708.
   PubMed Web of Science ®Google Scholar
• Staessen J, Lijnen P, Fagard R, et al. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol. 1981;91(3):457–465.
   PubMed Web of Science ®Google Scholar
• Mehmood K, Naqvi IH, Shah SR, et al. Waldenstroms macroglobulinemia patient presenting with rare ‘lytic’ lesions and hypercalcemia: a diagnostic dilemma. J Clin Diagn Res. 2014 Nov;8(11):FD10–1.
   PubMedGoogle Scholar
• Weber KT. Aldosterone in congestive heart failure. N Engl J Med. 2001;345(23):1689–1697.
   PubMed Web of Science ®Google Scholar
• Briet M, Schiffrin EL. Aldosterone: effects on the kidney and cardiovascular system. Nat Rev Nephrol. 2010;6(5):261–273.
   PubMed Web of Science ®Google Scholar
• Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341(10):709–717.
   PubMed Web of Science ®Google Scholar
• Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309–1321.
   PubMed Web of Science ®Google Scholar
• Shah SR. Smartphone healthcare: technology comes with caution! Perspect Public Health. 2014 Nov;134(6):320.
   PubMed Web of Science ®Google Scholar
• Edwards NC, Steeds RP, Stewart PM, et al. Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease. A randomized controlled trial. J Am Coll Cardiol. 2009;54(6):505–512.
   PubMed Web of Science ®Google Scholar
• Taheri S, Mortazavi M, Pourmoghadas A, et al. A prospective double-blind randomized placebo-controlled clinical trial to evaluate the safety and efficacy of spironolactone in patients with advanced congestive heart failure on continuous ambulatory peritoneal dialysis. Saudi J Kidney Dis Transplant. 2012;23(3):507–512.
   PubMedGoogle Scholar
• Chua D, Lo A, Lo C. Spironolactone use in heart failure patients with end-stage renal disease on hemodialysis: is it safe? Clin Cardiol. 2010;33(10):604–608.
   PubMed Web of Science ®Google Scholar
• The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336(8):525–533.
   PubMed Web of Science ®Google Scholar
• Shlipak MG, Smith GL, Rathore SS, et al. Renal function, digoxin therapy, and heart failure outcomes: evidence from the digoxin intervention group trial. J Am Soc Nephrol. 2004;15(8):2195–2203.
   PubMed Web of Science ®Google Scholar
• Ahmed A, Rich MW, Love TE, et al. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J. 2006;27(2):178–186.
   PubMed Web of Science ®Google Scholar
• Thiemann DR. Digitalis and hemodialysis is a bad combination. J Am Soc Nephrol. 2010;21(9):1418–1420.
   PubMed Web of Science ®Google Scholar
• Chan KE, Lazarus JM, Hakim RM. Digoxin associates with mortality in ESRD. J Am Soc Nephrol. 2010;21(9):1550–1559.
   PubMed Web of Science ®Google Scholar
• Shah SR, Tunio SA, Arshad MH, et al. Acute kidney injury recognition and management: a review of the literature and current evidence. Glob J Health Sci. 2015 Sep 18;8(5):120–124.
   PubMedGoogle Scholar
• Joannides R, Moore N, Iacob M, et al. Comparative effects of ivabradine, a selective heart rate-lowering agent, and propranolol on systemic and cardiac haemodynamics at rest and during exercise. Br J Clin Pharmacol. 2006;61(2):127–137.
   PubMed Web of Science ®Google Scholar
• Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353(9169):2001–2007.
   PubMed Web of Science ®Google Scholar
• Swedberg K, Komajda M, Böhm M, et al. SHIFT investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study [published correction appears in Lancet. 2010;376(9757):1988]. Lancet. 2010;376(9744):875–885.
   PubMed Web of Science ®Google Scholar
• FDA news release: FDA approves new drug to treat heart failure. U.S. Food and Drug Administration.2015. [Cited June 12, 2017]. Available from:http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm453845.htm.
   Google Scholar
• Vinereanu D. Sacubitril-valsartan for heart failure: from devil’s advocate to evidence-based medicine. Am J Ther. 2017;24(2):109–110.
   Web of Science ®Google Scholar
• Zheng SL, Roddick AJ, Ayis S. Effects of aliskiren on mortality, cardiovascular outcomes and adverse events in patients with diabetes and cardiovascular disease or risk: a systematic review and meta-analysis of 13,395 patients. Diab Vasc Dis Res. 2017 Sep; 14(5):400–406.
   PubMed Web of Science ®Google Scholar
• Pantzaris ND, Karanikolas E, Tsiotsios K, et al. Renin Inhibition with Aliskiren: a decade of clinical experience. J Clin Med. 2017 Jun 9;6(6):pii: E61.
   PubMed Web of Science ®Google Scholar
• Márquez DF, Ruiz-Hurtado G, Ruilope LM, et al. An update of the blockade of the renin angiotensin aldosterone system in clinical practice. Expert Opin Pharmacother. 2015;16(15):2283–2292.
   PubMed Web of Science ®Google Scholar
• Mann DL, McMurray JJV, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the randomized etanercept worldwide evaluation (RENEWAL). Circulation. 2004;109(13):1594–1602.
   PubMed Web of Science ®Google Scholar
• Shah SR, Altaf A, Arshad MH, et al. Use of cyclosporine therapy in steroid resistant nephrotic Syndrome (SRNS): a review. Glob J Health Sci. 2015. Aug 6; 8(4):136–141.
   Google Scholar
• Packer M, Califf RM, Konstam MA, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the omapatrilat versus enalapril randomized trial of utility in reducing events (OVERTURE). Circulation. 2002;106(8):920–926.
   PubMed Web of Science ®Google Scholar
• Nakano Y, Mizuno T, Niwa T, et al. Impact of continuous administration of tolvaptan on preventing medium-term worsening renal function and long-term adverse events in heart failure patients with chronic kidney disease. Int Heart J. 2018 Jan 15. DOI:10.1536/ihj.16-625
   PubMedGoogle Scholar
• Sata Y, Krum H. The future of pharmacological therapy for heart failure. Circ J. 2010;74(5):809–817.
   PubMed Web of Science ®Google Scholar